Brief: Sino Biopharmaceutical Announces Acceptance Of New Drug Application
18/07/2024 12:29
July 18 (Reuters) - Sino Biopharmaceutical Ltd
1177.HK :
* ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1
INNVOATIVE
DRUG CULMERCICLIB CAPSULE CULMERCICLIB (TQB3616)
* ACCEPTANCE BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up